[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356596-105":59,"doc-detail-356596-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outsmarting-metastatic-prostate-cancer-integration-of-imaging-liquid-biopsies-and-biomarkers-with-artificial-intelligence","Outsmarting Metastatic Prostate Cancer - Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence","","Management of metastatic prostate cancer presents major difficulties driven by tumor heterogeneity and therapeutic resistance. Progress in molecular imaging, liquid biopsies, and biomarker research supports precision oncology, while artificial intelligence using machine learning and deep learning can synthesize complex datasets for improved diagnostic accuracy, risk stratification, and treatment guidance. This review describes AI applications for imaging, cell-free nucleic acids, circulating tumor cells, and genomic classifiers, and discusses deployment opportunities and challenges requiring multimodal integration and real-world validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outsmarting-metastatic-prostate-cancer-integration-of-imaging-liquid-biopsies-and-biomarkers-with-artificial-intelligence/356596/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outsmarting-metastatic-prostate-cancer-integration-of-imaging-liquid-biopsies-and-biomarkers-with-artificial-intelligence/356596.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is metastatic prostate cancer management particularly challenging?","Question",{"text":112,"@type":113},"Management is difficult due to tumor heterogeneity and therapeutic resistance, which make outcomes variable and unpredictable.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do imaging, liquid biopsies, and biomarkers contribute to precision oncology?",{"text":117,"@type":113},"They enable molecular-level insights that can improve diagnostic accuracy, risk stratification, and treatment guidance, especially when integrated into precision oncology workflows.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does artificial intelligence play in this review’s approach?",{"text":121,"@type":113},"The review emphasizes AI applications, including machine learning and deep learning, to integrate complex multimodal datasets and support decision-making for more personalized treatments.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356596,1790203903,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence  \nTechnology in Cancer Research & Treatment Volume 25: 1–26 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/15330338261440434](DOI: 10.1177/15330338261440434)  \n[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nJun-Xian He1, Luyuan Li2 , Shuhong Chen3, Rong-Jun Chen4, Jia-Le Zhuang4, Chang Liu4, Wesley Burrow5, Jonghoon Chang5, Tanziela Tanziela4, R. Daniel Bonfil5 , Nai-Kei Wong4, and Wensi Tao5   \nAbstract  \nManagement of metastatic prostate cancer (mPCa) poses significant challenges due to inherent tumor heterogeneity and therapeutic resistance. Advances in molecular imaging, liquid biopsies, and biomarkers are enabling precision oncology, while artificial intelligence (AI), including machine learning (ML) and deep learning (DL), integrates complex datasets to improve diagnostic accuracy, risk stratification, and treatment guidance. This review highlights AI’s applications in mPCa, focusing on imaging, cell-free nucleic acids, circulating tumor cells, and genomic classifiers. We emphasize AI’s role in enhancing diagnostics and personalizing treatments, with implications for improving clinical outcomes through better decision-making. Finally, we discuss opportunities and challenges in deploying AI systems, stressing multimodal integration and validation for real-world clinical impact.  \nKeywords  \nmetastatic prostate cancer, artificial intelligence, deep learning, medical imaging, biomarker, diagnosis, prognosis Received: 1 October 2025; Revised: 11 March 2026; Accepted: 23 March 2026  \n1. Introduction  \nProstate cancer (PCa) remains one of the leading causes of cancer-related mortality, 1 and the most frequently diagnosed malignancy among men in the United States2 and Europe.3,4 Metastatic prostate cancer (mPCa), particularly in its castrationresistant form (CRPC), accounts for a large proportion of prostate cancer-related deaths. The primary risk factors for PCa include African ancestry,5 and advancing age.6 Additional contributors include genetic mutation,7 family history,8 smoking,9 obesity and diets high in fat.10 Although recent advances, such as androgen receptor (AR) targeted therapies, taxanes, radioligands, and PARP inhibitors have expanded therapeutic options, outcomes remain variable and unpredictable, largely due to the profound intra-and inter-tumor heterogeneity of the disease.  \n1School of Electronics and Communication Engineering, Guangzhou University, Guangzhou, China 2Department of Medicine, North Alabama Medical Center, Florence, AL, USA  \n3School of Computer Science and Cyber Engineering, Guangzhou University, Guangzhou, China  \n4Clinical Pharmacology Section, Department of Pharmacology, Shantou University Medical College, Shantou, China  \n5Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA  \nCorresponding authors:  \nWensiTao, Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA. [Email:](Email: wtao@nova.edu)[ wtao@nova.edu](Email: wtao@nova.edu)  \nNai-Kei Wong, Clinical Pharmacology Section, Department of Pharmacology, Shantou University Medical College, Shantou 515041, China. [Email:](Email: wongnk@stu.edu.cn)[ wongnk@stu.edu.cn](Email: wongnk@stu.edu.cn)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.","cbCailanQcV4S9aE","https://ap.wps.com/l/cbCailanQcV4S9aE","pdf",3721858,26,"English","# Introduction\n## Metastatic prostate cancer challenges\n## Current diagnostic and treatment pathway\n# AI integration in oncology\n## Clinical workflows and adaptive strategies","[{\"question\":\"Why is metastatic prostate cancer management particularly challenging?\",\"answer\":\"Management is difficult due to tumor heterogeneity and therapeutic resistance, which make outcomes variable and unpredictable.\"},{\"question\":\"How do imaging, liquid biopsies, and biomarkers contribute to precision oncology?\",\"answer\":\"They enable molecular-level insights that can improve diagnostic accuracy, risk stratification, and treatment guidance, especially when integrated into precision oncology workflows.\"},{\"question\":\"What role does artificial intelligence play in this review’s approach?\",\"answer\":\"The review emphasizes AI applications, including machine learning and deep learning, to integrate complex multimodal datasets and support decision-making for more personalized treatments.\"}]","Outsmarting Metastatic Prostate Cancer - Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence | PDF",1790126125,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/293b72e5215c7c1104ee71439b7678af.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38a2a0606e3832434561aa752f74b427.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e38ab733a37c633ef634844b41af3a7.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59881d7a33934f6a674fab2e794b66e7.webp",980,1306]